Clinical Trial Update: Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 trial evaluating rituximab plus intravenous immunoglobulin (IVIG) for desensitization in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)
• Rituxan (rituximab)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Kidney Transplant | Phase 1, Phase 2 | Status: COMPLETED